The number of “baby-boomers,” often defined as persons born during the period from 1946 to 1964, peaked at almost 79 million in the 2000 U.S. Census. As this massive group dominates the population within the U.S., important issues relating to productivity are arising along with imminent changes in the labor force caused by the exit [...]
There are several contraindications for the use of FluMist™: 1. Under no circumstances should the vaccine be administered parenterally. 2. Individuals with a history of hyper-sensitivity—especially anaphylactic reactions—to any component of Flu-Mist™, including eggs or egg products, should not receive this vaccine. 3. FluMist™ should not be given to children (ages five to 17) who [...]
A multicenter, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy of FluMist™ in reducing influenza illness during a seven-week, site-specific peak outbreak period. The trial included 3,920 healthy adults aged 18 to 49 throughout the U.S. who were randomly selected to receive the vaccine or a placebo (in a ratio of 2:1).
FluMist™ is an intranasal, live, attenuated, trivalent, cold-adapted, and temperature-sensitive vaccine. The immune mechanisms that confer protection against influenza following administration of this vaccine are not fully understood, and naturally acquired immunity to wild-type influenza has not been completely clarified. It is possible that serum antibodies, mucosal antibodies, and influenza-specific T cells might be involved [...]
INTRODUCTION Influenza, commonly referred to as the flu, is an acute, contagious, and self-limited disease that directly affects the respiratory tract. Approximately 10% to 20% of Americans experience illness because of influenza each year, resulting in a significant loss in work and productivity that directly and indirectly translates into financial costs. Each year, from $3 [...]
A substantial risk of relapse is associated with the discontinuation of antidepressant therapy after the acute symptoms of a depressive episode resolve. It is widely recognized that an additional four to six months of continued treatment is needed to consolidate patient response and to prevent relapse. Rapaport et al. conducted a multicenter trial to determine [...]
Rationale for Development From the preceding discussion, it is evident that no single agent appears to share all the characteristics of the ideal anti-depressant drug (i.e., rapid onset of action, a short half-life, minimal discontinuation effects, an absence of ADEs, negligible drug interactions, a broad spectrum of activity, and low cost). Efforts to develop better [...]
© 2008 HIV/AIDS News & Information